Literature DB >> 27621198

Sialidoses.

Silvana Franceschetti1, Laura Canafoglia1.   

Abstract

Sialidoses are autosomal recessive disorders caused by NEU1 gene mutations and are classified on the basis of their phenotype and onset age. Sialidosis type II, with infantile onset, has a more severe phenotype characterized by coarse facial features, hepatomegaly, dysostosis multiplex, and developmental delay while patients with the late and milder type, known as "cherry red spot-myoclonus syndrome" develop myoclonic epilepsy, visual impairment and ataxia in the second or third decade of life. The diagnosis is usually suggested by increased urinary bound sialic acid excretion. We recently described genetically diagnosed patients with a specially mild phenotype, no retinal abnormalities and normal urinary sialic acid. This observation suggests that genetic analysis or the demonstration of the neuraminidase enzyme deficiency in cultured fibroblasts are needed to detect and diagnose mildest phenotypes.

Entities:  

Keywords:  NEU1; cortical myoclonus; cortico-muscolar coherence; neuraminidase; progressive myoclonus epilepsies

Mesh:

Year:  2016        PMID: 27621198     DOI: 10.1684/epd.2016.0845

Source DB:  PubMed          Journal:  Epileptic Disord        ISSN: 1294-9361            Impact factor:   1.819


  16 in total

Review 1.  The best evidence for progressive myoclonic epilepsy: A pathway to precision therapy.

Authors:  Alessandro Orsini; Angelo Valetto; Veronica Bertini; Mariagrazia Esposito; Niccolò Carli; Berge A Minassian; Alice Bonuccelli; Diego Peroni; Roberto Michelucci; Pasquale Striano
Journal:  Seizure       Date:  2019-08-23       Impact factor: 3.184

2.  Clinical and genetic characteristics of type I sialidosis patients in mainland China.

Authors:  Rui-Juan Lv; Tao-Ran Li; Yu-Di Zhang; Xiao-Qiu Shao; Qun Wang; Li-Ri Jin
Journal:  Ann Clin Transl Neurol       Date:  2020-05-29       Impact factor: 4.511

Review 3.  Myoclonus-Ataxia Syndromes: A Diagnostic Approach.

Authors:  Malco Rossi; Sterre van der Veen; Marcelo Merello; Marina A J Tijssen; Bart van de Warrenburg
Journal:  Mov Disord Clin Pract       Date:  2020-11-03

4.  Clinical Exome Sequencing Enables Congenital Sialidosis Type II Diagnosis in Two Siblings Presenting with Unreported Clinical Features from a Rare Homozygous Sequence Variant p.(Tyr370Cys) in NEU1.

Authors:  Elda Ariadna Flores-Contreras; José Elías García-Ortiz; Carla Daniela Robles-Espinoza; Viviana Zomosa-Signoret; Luis Eduardo Becerra-Solano; Román Vidaltamayo; Carolina Castaneda-García; Eduardo Esparza-García; Christian Molina-Aguilar; Angélica Alejandra Hernández-Orozco; Carlos Córdova-Fletes
Journal:  Mol Syndromol       Date:  2021-06-17

5.  Type 1 sialidosis presenting with ataxia, seizures and myoclonus with no visual involvement.

Authors:  Ahmed N Mohammad; Katelyn A Bruno; S Hines; Paldeep S Atwal
Journal:  Mol Genet Metab Rep       Date:  2018-01-12

6.  Using Bibliometric Analysis and Machine Learning to Identify Compounds Binding to Sialidase-1.

Authors:  Jennifer J Klein; Nancy C Baker; Daniel H Foil; Kimberley M Zorn; Fabio Urbina; Ana C Puhl; Sean Ekins
Journal:  ACS Omega       Date:  2021-01-20

Review 7.  Abnormal Sphingolipid World in Inflammation Specific for Lysosomal Storage Diseases and Skin Disorders.

Authors:  Marta Moskot; Katarzyna Bocheńska; Joanna Jakóbkiewicz-Banecka; Bogdan Banecki; Magdalena Gabig-Cimińska
Journal:  Int J Mol Sci       Date:  2018-01-15       Impact factor: 5.923

Review 8.  Sialidosis: A Review of Morphology and Molecular Biology of a Rare Pediatric Disorder.

Authors:  Aiza Khan; Consolato Sergi
Journal:  Diagnostics (Basel)       Date:  2018-04-25

Review 9.  Nomenclature of Genetically Determined Myoclonus Syndromes: Recommendations of the International Parkinson and Movement Disorder Society Task Force.

Authors:  Sterre van der Veen; Rodi Zutt; Christine Klein; Connie Marras; Samuel F Berkovic; John N Caviness; Hiroshi Shibasaki; Tom J de Koning; Marina A J Tijssen
Journal:  Mov Disord       Date:  2019-10-04       Impact factor: 10.338

10.  Neuraminidase-1 promotes heart failure after ischemia/reperfusion injury by affecting cardiomyocytes and invading monocytes/macrophages.

Authors:  Maren Heimerl; Irina Sieve; Melanie Ricke-Hoch; Sergej Erschow; Karin Battmer; Michaela Scherr; Denise Hilfiker-Kleiner
Journal:  Basic Res Cardiol       Date:  2020-09-25       Impact factor: 17.165

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.